Bicoll breaks even and looks to new projects

The private Sino-German bioventure, Bicoll, has moved to its first annual after-tax profit after three years of operations, helped by several agreements with pharmaceutical industry and research institution customers. The group provides a range of combinatorial chemistry, structural biology/chemistry,
screening and lead identification/optimisation services related to compounds isolated from rare Asian natural plant resources. The positive cash flow will also allow it to progress a number of in-house preclinical projects, which include potential products for cancer, type 2 diabetes, Alzheimer’s disease and tuberculosis, managing director Dr. Kai Lamottke said.
BIO International 2024June 3-6
+ +